This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pisoni, C. Articles by Cuadrado, M. Search for Related Content PubMed PubMed Citation Articles by Pisoni, C. Articles by Cuadrado, M. Social Bookmarking                         What's this?

Mycophenolate mofetil and systemic lupus erythematosus: an overview

Lupus Research Unit, St Thomas' Hospital, London, UK

Y. Karim

Lupus Research Unit, St Thomas' Hospital, London, UK

MJ Cuadrado

Lupus Research Unit, St Thomas' Hospital, London, UK

Mycophenolate mofetil (MMF) is an immunosuppressive agent used in transplantation, with evidence of superior protection against acute transplant rejection compared to azathioprine-containing regimens. Subsequently MMF has been used in a variety of autoimmune conditions. The major experience in systemic lupus erythematosus (SLE) has focused on proliferative lupus nephritis. Following its success in the treatment of lupus nephritis, MMF is now being used to control other SLE manifestations such as, lupus disease activity, haematological manifestations and resistant skin lupus. In this review, we discuss our own experience and the literature report about the use of MMF in SLE. Lupus (2005) 14, s9-s11.

Key Words: lupus disease activity • lupus nephritis • mycophenolate mofetil • systemic lupus erythematosus • treatment

Lupus, Vol. 14, No. 1 suppl, s9-s11 (2005)
DOI: 10.1177/096120330501400103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?